This is a working overview of Ion-pairing chromatography, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide mononucleotide | Often abbreviated NMN |
| Chemical formula | C11H15N2O8P | Beta anomer form |
| Molecular mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | Beta-NMN |
| Appearance | White to off-white powder | Typical laboratory grade |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
In November 2001, the Food and Drug Administration approved Drotrecogin alfa-activated (DrotAA) for the clinical treatment of adults suffering from severe sepsis and with a high risk of death. Drotrecogin alfa-activated is a recombinant form of human activated protein C (rhAPC). It is marketed as Xigris by Eli Lilly and Company, Drotrecogin alfa-activated was the subject of significant controversy while it was approved for clinical use as it was found to increase bleeding and not to reduce mortality. In October 2011 rhAPC (Xigris) was withdrawn from the market by Eli Lilly due to a higher mortality in a trial among adults. APC has been studied as way of treating lung injury, after studies showed that in patients with lung injury, reduced APC levels in specific parts of the lungs correlated with worse outcomes. APC also has been considered for use in improving patient outcome in cases of ischemic stroke, a medical emergency in which arterial blockage deprives a region of brain of oxygen, causing tissue death. Promising studies suggest that APC could be coupled with the only currently approved treatment, tissue plasminogen activator (tPA), to protect the brain from tPA's very harmful side effects, in addition to preventing cell death from lack of oxygen (hypoxia). Clinical use of APC has also been proposed for improving the outcome of pancreatic islet transplantation in treating type I diabetes. Ceprotin was approved for medical used in the European Union in July 2001.
R = universal gas constant m = number of occupied lattice sites per molecule (for polymer solutions m1 is approximately equal to the degree of polymerization and m2=1) φ = volume fraction of the polymer and the solvent, respectively χ = interaction parameter A consequence of the Flory-Huggins theory is, for instance, that the UCST (if it exists) increases and shifts into the solvent-rich region when the molar mass of the polymer increases. Whether a polymer shows LCST and/or UCST behavior can be derived from the temperature-dependence of the interaction parameter (see figure). The interaction parameter not only comprises enthalpic contributions but also the non-ideal entropy of mixing, which again consists of many individual contributions (e.g., the strong hydrophobic effect in aqueous solutions). For these reasons, classical Flory-Huggins theory cannot provide much insight into the molecular origin of miscibility gaps.
== Structure == The phytaspase displays a structure, common to the subtilisin-like proteases. Its N-terminus includes a prodomain, which commonly inhibits subtilisin-like proteases and undergoes an autocatalytic cleavage during maturation, followed by a protease domain, which includes and adheres the common order of the sequence of the three canonic catalytic amino acid residues, and a prolonged C-terminal domain.
Sources: en.wikipedia.org
Cuny further pointed out that "studies of every recent famine have shown that food was available in-country—though not always in the immediate food deficit area" and "even though by local standards the prices are too high for the poor to purchase it, it would usually be cheaper for a donor to buy the hoarded food at the inflated price than to import it from abroad."
The legendary religious zeal of the Normans was exercised in religious wars long before the First Crusade carved out a Norman principality in Antioch. They were major foreign combatants in the Reconquista in Iberia. In 1018, Roger de Tosny travelled to the Iberian Peninsula to carve out a state for himself from Moorish lands, but failed. In 1064, during the War of Barbastro, William of Montreuil, Roger Crispin and probably Walter Guiffard led an army under the papal banner which took a huge booty as they captured the city from its Andelusi rulers. Later a group of Normans led by a certain William (some have suggested this was William the Carpenter) participated in the failed siege of Tudela of 1087. In 1096, Crusaders passing by the siege of Amalfi were joined by Bohemond of Taranto and his nephew Tancred with an army of Italo-Normans. Bohemond was the de facto leader of the Crusade during its passage through Asia Minor. After the successful Siege of Antioch in 1097, Bohemond began carving out an independent principality around that city. Tancred was instrumental in the conquest of Jerusalem and he worked for the expansion of the Crusader kingdom in Transjordan and the region of Galilee.. After the First Crusade to the Levant, the Normans continued with their involvement in Iberia as well as other areas of the Mediterranean. Among them was Rotrou of Perche and his followers Robert Burdet and William Giffard who joined multiple expeditions into the Ebro Valley to aid Alfonso I of Aragon in his campaigns of conquest.
Coronary artery disease, also known as ischemic heart disease, is caused by atherosclerosis—a build-up of fatty material along the inner walls of the arteries. These fatty deposits known as atherosclerotic plaques narrow the coronary arteries, and if severe may reduce blood flow to the heart. If a narrowing (or stenosis) is relatively minor then the patient may not experience any symptoms. Severe narrowings may cause chest pain (angina) or breathlessness during exercise or even at rest. The thin covering of an atherosclerotic plaque can rupture, exposing the fatty centre to the circulating blood. In this case a clot or thrombus can form, blocking the artery, and restricting blood flow to an area of heart muscle causing a myocardial infarction (a heart attack) or unstable angina. In the worst case this may cause cardiac arrest, a sudden and utter loss of output from the heart. Obesity, high blood pressure, uncontrolled diabetes, smoking and high cholesterol can all increase the risk of developing atherosclerosis and coronary artery disease.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.
No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.
Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.